Double drug attack shows promise against tough head and neck cancers
NCT ID NCT02979977
First seen Feb 04, 2026 · Last updated Jun 11, 2026 · Updated 21 times
Summary
This study tested a combination of two targeted drugs, afatinib and cetuximab, in 50 adults with advanced head and neck cancer that had already been treated with chemotherapy or immunotherapy. The goal was to see if the drug pair could shrink tumors. While the treatment aims to control the disease, it is not a cure, and patients may need ongoing management.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SQUAMOUS CELL CANCERS OF THE HEAD AND NECK are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Yale Cancer Center
New Haven, Connecticut, 06520-8028, United States
Conditions
Explore the condition pages connected to this study.